New Issue: Orbital Catastrophe Ahead? Read Now

Antibody Cocktail Battles Botulism

Join Our Community of Science Lovers!


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Researchers have developed a potent weapon against the paralyzing disease botulism. The affliction results from exposure to botulinum neurotoxin (BoNT), which is secreted by a soil bacterium called Clostridium botulinum. The most poisonous substance known, just a gram of BoNT could kill a million people if evenly dispersed and inhaled. As such, it ranks among the Centers for Disease Control and Prevention¿s six highest-risk threat agents for bioterrorism. At the moment, no anti-botulism treatments capable of being produced on a large scale are available. But a new drug described in a report published online this week by the Proceedings of the National Academy of Sciences both neutralizes the toxin very effectively in mice and apparently can be readily mass-produced and stockpiled.

The drug consists of three antibodies, each of which binds to a different part of the botulinum toxin. Together they squelch far more of the toxin than they would individually. "This approach has allowed us to develop a drug consisting of only a few antibodies which neutralizes toxin better than the most potent natural immune response," says team member James D. Marks of the University of California at San Francisco. And because the antibody genes are cloned into a manufacturing cell line, cultured cells could conceivably churn out an unlimited supply of the antibodies.

So far, the researchers have shown the drug to work in mice against one of the four BoNT types known to cause botulism. But they suspect that such cocktails of multiple antibodies, or oligoclonal Abs, will one day combat a wide array of diseases caused by other pathogens and biologic threat agents. Indeed, the team concludes that its findings support "the rapid development and evaluation of oligoclonal Ab for countering BoNT and other agents of biowarfare and bioterrorism."

Kate Wong is an award-winning science writer and was formerly senior editor for features at Scientific American, where she focused on evolution, ecology, anthropology, archaeology, paleontology and animal behavior. She is fascinated by human origins, which she has covered for nearly 30 years. Recently she has become obsessed with birds. Her reporting has taken her to caves in France and Croatia that Neandertals once called home to the shores of Kenya’s Lake Turkana in search of the oldest stone tools in the world, as well as to Madagascar on an expedition to unearth ancient mammals and dinosaurs, the icy waters of Antarctica, where humpback whales feast on krill, and a “Big Day” race around the state of Connecticut to find as many bird species as possible in 24 hours. Wong is co-author, with Donald Johanson, of Lucy’s Legacy: The Quest for Human Origins. She holds a bachelor of science degree in biological anthropology and zoology from the University of Michigan. Follow her on Bluesky @katewong.bsky.social

More by Kate Wong

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe